Cessatech (CESSA) Stock Overview
A pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CESSA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cessatech A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 12.18 |
| 52 Week High | DKK 15.78 |
| 52 Week Low | DKK 6.00 |
| Beta | 0.51 |
| 1 Month Change | 18.95% |
| 3 Month Change | 0.83% |
| 1 Year Change | -8.76% |
| 3 Year Change | 466.51% |
| 5 Year Change | n/a |
| Change since IPO | 4.10% |
Recent News & Updates
Shareholder Returns
| CESSA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 5.0% | -0.9% | -1.0% |
| 1Y | -8.8% | 2.6% | 3.7% |
Return vs Industry: CESSA underperformed the Swedish Pharmaceuticals industry which returned 2.6% over the past year.
Return vs Market: CESSA underperformed the Swedish Market which returned 3.7% over the past year.
Price Volatility
| CESSA volatility | |
|---|---|
| CESSA Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: CESSA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CESSA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Jes Trygved | www.cessatech.com |
Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel.
Cessatech A/S Fundamentals Summary
| CESSA fundamental statistics | |
|---|---|
| Market cap | DKK 228.86m |
| Earnings (TTM) | -DKK 17.35m |
| Revenue (TTM) | n/a |
Is CESSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CESSA income statement (TTM) | |
|---|---|
| Revenue | -DKK 4.60m |
| Cost of Revenue | -DKK 3.20m |
| Gross Profit | -DKK 1.39m |
| Other Expenses | DKK 15.95m |
| Earnings | -DKK 17.35m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 30.33% |
| Net Profit Margin | 377.19% |
| Debt/Equity Ratio | 0% |
How did CESSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 20:17 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cessatech A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.